Physician profile
Lawrence D Chang
NPI 1275577843
$160,136.00
in general payments reported to CMS, 2019-2025
21 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $282 · 2021: $124 · 2022: $183 · 2023: $260 · 2024: $37K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $144K · Travel and Lodging: $9,503 · Food and Beverage: $4,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $144,234.25 |
| Travel and Lodging | $9,502.81 |
| Food and Beverage | $4,600.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $157,108.28 | 2024-2025 | Innovamatrix Ac |
| Merz North America, INC. | $792.01 | 2019 | |
| Allergan, INC. | $576.64 | 2019-2022 | |
| Abbvie INC. | $445.05 | 2023-2025 | Botox |
| Regeneron Healthcare Solutions, INC. | $319.42 | 2022-2024 | Libtayo |
| Galderma Laboratories, L.P. | $245.99 | 2020-2025 | Dysport |
| Mentor Worldwide LLC | $195.06 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Tela Bio, INC. | $117.86 | 2020-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kerecis Limited | $49.33 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Baxter Healthcare | $49.24 | 2024 | Perclot |
| Stryker Corporation | $43.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.36 | 2022 | |
| Molnlycke Health Care US, LLC | $22.00 | 2024 | Mepilex Border Post-Op Ag, Mepilex Border Flex, Mepilex Border Post-Op |
| Tei Biosciences INC | $20.98 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $20.75 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $19.28 | 2021 | |
| Avanos Medical | $18.96 | 2022 | |
| Novo Nordisk INC | $18.48 | 2023 | Wegovy |
| Solta Medical, A Division of Bausch Health US, LLC | $16.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2022 | |
| Dusa Pharmaceuticals, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.